A transposon and transposase system for human application

Molecular Therapy

Volumn 18, Issue 4, 2010, Pages 674-683

  Hackett, Perry B ^a   Largaespada, David A ^a   Cooper, Laurence J N ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC PROTEIN; OKT 3; RETROVIRUS VECTOR; TRANSPOSASE;

ADRENOLEUKODYSTROPHY; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENOTOXICITY; GOOD MANUFACTURING PRACTICE; HEMATOPOIETIC STEM CELL; HUMAN; INVERTED TERMINAL REPEAT; MALIGNANT TRANSFORMATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; REVIEW; RISK ASSESSMENT; SEVERE COMBINED IMMUNODEFICIENCY; SLEEPING BEAUTY; T LYMPHOCYTE; TRANSPOSON;

ANIMALS; ANTIGENS, CD19; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DNA TRANSPOSABLE ELEMENTS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; PLASMIDS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPOSASES;

EID: 77950525914     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.2     Document Type: Review

References (123)

1. Kay, MA, Glorioso, JC and Naldini, L (2001). Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7: 33-40. (Pubitemid 32095639)
2. Lozier, JN, Csako, G, Mondoro, TH, Krizek, DM, Metzger, ME, Costello, R et al. (2002). Toxicity of a frst-generation adenoviral vector in rhesus macaques. Hum Gene Ther 13: 113-124. (Pubitemid 34075175)
3. Graham, A, Walker, R, Baird, P, Hahn, CN and Fazakerley, JK (2006). CNS gene therapy applications of the Semliki Forest virus 1 vector are limited by neurotoxicity. Mol Ther 13: 631-635. (Pubitemid 43257632)
4. Henikoff, S (1998). Conspiracy of silence among repeated transgenes. Bioessays 20: 532-535. (Pubitemid 28362298)
5. Selker, EU (1999). Gene silencing: repeats that count. Cell 97: 157-160.
6. Bestor, TH (2000). Gene silencing as a threat to the success of gene therapy. J Clin Invest 105: 409-411. (Pubitemid 30127239)
7. Izsvák, Z and Ivics, Z (2004). Sleeping Beauty transposition: biology and applications for molecular therapy. Mol Ther 9: 147-156. (Pubitemid 38256540)
8. Hackett, PB, Ekker, SC, Largaespada, DA and McIvor, RS (2005). Sleeping Beauty transposon-mediated gene therapy for prolonged expression. Adv Genet 54: 189-232. (Pubitemid 43591151)
9. VandenDriessche, T, Ivics, Z, Izsvák, Z and Chuah, MK (2009). Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 114: 1461-1468.
10. Ivics, Z, Hackett, PB, Plasterk, RH and Izsvák, Z (1997). Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fsh, and its transposition in human cells. Cell 91: 501-510. (Pubitemid 27508239)
11. Izsvák, Z, Ivics, Z and Hackett, PB (1995). Characterization of a Tc1-like transposable element in zebrafsh (Danio rerio). Mol Gen Genet 247: 312-322.
12. Ivics, Z, Izsvak, Z, Minter, A and Hackett, PB (1996). Identifcation of functional domains and evolution of Tc1-like transposable elements. Proc Natl Acad Sci USA 93: 5008-5013. (Pubitemid 26162862)
13. Carlson, CM and Largaespada, DA (2005). Insertional mutagenesis in mice: new perspectives and tools. Nat Rev Genet 6: 568-580.
14. Ivics, Z and Izsvák, Z (2005). A whole lotta jumpin' goin' on: new transposon tools for vertebrate functional genomics. Trends Genet 21: 8-11. (Pubitemid 40178841)
15. Geurts, AM, Yang, Y, Clark, KJ, Liu, G, Cui, Z, Dupuy, AJ et al. (2003). Gene transfer into genomes of human cells by the Sleeping Beauty transposon system. Mol Ther 8: 108-117. (Pubitemid 36939302)
16. Yant, SR, Park, J, Huang, Y, Mikkelsen, JG and Kay, MA (2004). Mutational analysis of the N-terminal DNA-binding domain of Sleeping Beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol 24: 9239-9247. (Pubitemid 39313924)
17. Baus, J, Liu, L, Heggestad, AD, Sanz, S and Fletcher, BS (2005). Hyperactive transposase mutants of the Sleeping Beauty transposon. Mol Ther 12: 1148-1156. (Pubitemid 41723049)
18. Mátés, L, Chuah, MK, Belay, E, Jerchow, B, Manoj, N, Acosta-Sanchez, A et al. (2009). Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 41: 753-761.
19. Izsvák, Z, Khare, D, Behlke, J, Heinemann, U, Plasterk, RH and Ivics, Z (2002). Involvement of a bifunctional, paired-like DNA-binding domain and a transpositional enhancer in Sleeping Beauty transposition. J Biol Chem 277: 34581-34588.
20. Cui, Z, Geurts, AM, Liu, G, Kaufman, CD and Hackett, PB (2002). Structure-function analysis of the inverted terminal repeats of the Sleeping Beauty transposon. J Mol Biol 318: 1221-1235. (Pubitemid 34753993)
21. Yant, SR, Meuse, L, Chiu, W, Ivics, Z, Izsvak, Z and Kay, MA (2000). Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 25: 35-41. (Pubitemid 30257033)
22. Yant, SR, Ehrhardt, A, Mikkelsen, JG, Meuse, L, Pham, T and Kay, MA (2002). Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 20: 999-1005.
23. Ohlfest, JR, Frandsen, JL, Fritz, S, Lobitz, PD, Perkinson, SG, Clark, KJ et al. (2005). Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 105: 2691-2698. (Pubitemid 40446258)
24. Liu, L, Mah, C and Fletcher, BS (2006). Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted Sleeping Beauty transposon. Mol Ther 13: 1006-1015.
25. Kren, BT, Unger, GM, Sjeklocha, L, Trossen, AA, Korman, V, Diethelm-Okita, BM et al. (2009). Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 119: 2086-2099.
26. Montini, E, Held, PK, Noll, M, Morcinek, N, Al-Dhalimy, M, Finegold, M et al. (2002). In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther 6: 759-769. (Pubitemid 36054309)
27. Ortiz-Urda, S, Lin, Q, Yant, SR, Keene, D, Kay, MA and Khavari, PA (2003). Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther 10: 1099-1104. (Pubitemid 36850232)
28. He, CX, Shi, D, Wu, WJ, Ding, YF, Feng, DM, Lu, B et al. (2004). Insulin expression in livers of diabetic mice mediated by hydrodynamics-based administration. World J Gastroenterol 10: 567-572. (Pubitemid 38325316)
29. Chen, ZJ, Kren, BT, Wong, PY, Low, WC and Steer, CJ (2005). Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. Biochem Biophys Res Commun 329: 646-652.
30. Aronovich, EL, Bell, JB, Belur, LR, Gunther, R, Koniar, B, Erickson, DC et al. (2007). Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med 9: 403-415. (Pubitemid 46796586)
31. Aronovich, EL, Bell, JB, Khan, SA, Belur, LR, Gunther, R, Koniar, B et al. (2009). Systemic correction of storage disease in MPS I NOD/SCID mice using the Sleeping Beauty transposon system. Mol Ther 17: 1136-1144.
32. Ohlfest, JR, Lobitz, PD, Perkinson, SG and Largaespada, DA (2004). Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system. Mol Ther 10: 260-268.
33. Ohlfest, JR, Demorest, ZL, Motooka, Y, Vengco, I, Oh, S, Chen, E et al. (2005). Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the Sleeping Beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 12: 778-788. (Pubitemid 41614473)
34. Yant, SR, Wu, X, Huang, Y, Daigle, B, Garrison, BA, Burgess, SM et al. (2004). Nonrandom insertion site preferences for the SB transposon in vitro and in vivo. Mol Ther 9: S309-S310.
35. Geurts, AM, Hackett, CS, Bell, JB, Bergemann, TL, Collier, LS, Carlson, CM et al. (2006). Structure-based prediction of insertion-site preferences of transposons into chromosomes. Nucleic Acids Res 34: 2803-2811.
36. Berry, C, Hannenhalli, S, Leipzig, J and Bushman, FD (2006). Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol 2: e157. (Pubitemid 44819930)
37. Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
38. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
39. Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. (2009). Gene therapy for immunodefciency due to adenosine deaminase defciency. N Engl J Med 360: 447-458.
40. Hacein-Bey-Abina, S, Garrigue, A, Wang, G P, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
41. Deakin, CT, Alexander, IE and Kerridge, I (2009). Accepting risk in clinical research: is the gene therapy feld becoming too risk-averse? Mol Ther 17: 1842-1848.
42. Baum, C, von Kalle, C, Staal, FJ, Li, Z, Fehse, B, Schmidt, M et al. (2004). Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 9: 5-13. (Pubitemid 38208322)
43. Kustikova, O, Fehse, B, Modlich, U, Yang, M, Düllmann, J, Kamino, K et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174. (Pubitemid 40696434)
44. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. (Pubitemid 37296260)
45. Kustikova, OS, Schiedlmeier, B, Brugman, MH, Stahlhut, M, Bartels, S, Li, Z et al. (2009). Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 17: 1537-1547.
46. Yamada, K, Tsukahara, T, Yoshino, K, Kojima, K, Agawa, H, Yamashita, Y et al. (2009). Identifcation of a high incidence region for retroviral vector integration near exon 1 of the LMO2 locus. Retrovirology 6: 79.
47. Fehse, B and Roeder, I (2008). Insertional mutagenesis and clonal dominance: biological and statistical considerations. Gene Ther 15: 143-153.
48. June, CH, Blazar, BR and Riley, JL (2009). Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9: 704-716.
49. Newrzela, S, Cornils, K, Li, Z, Baum, C, Brugman, MH, Hartmann, M et al. (2008). Resistance of mature T cells to oncogene transformation. Blood 112: 2278-2286.
50. Kohn, DB, Sadelain, M, Dunbar, C, Bodine, D, Kiem, H P, Candotti, F et al.; American Society of Gene Therapy (ASGT) (2003). American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 8: 180-187. (Pubitemid 37062828)
51. Modlich, U, Kustikova, OS, Schmidt, M, Rudolph, C, Meyer, J, Li, Z et al. (2005). Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105: 4235-4246. (Pubitemid 40720768)
52. Shou, Y, Ma, Z, Lu, T and Sorrentino, BP (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 103: 11730-11735. (Pubitemid 44182519)
53. Woods, NB, Bottero, V, Schmidt, M, von Kalle, C and Verma, IM (2006). Gene therapy: therapeutic gene causing lymphoma. Nature 440: 1123.
54. Modlich, U, Navarro, S, Zychlinski, D, Maetzig, T, Knoess, S, Brugman, MH et al. (2009). Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17: 1919-1928.
55. Li, CL, Xiong, D, Stamatoyannopoulos, G and Emery, DW (2009). Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol Ther 17: 716-724.
56. Hematti, P, Hong, BK, Ferguson, C, Adler, R, Hanawa, H, Sellers, S et al. (2004). Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2: e423. (Pubitemid 40280522)
57. Calmels, B, Ferguson, C, Laukkanen, MO, Adler, R, Faulhaber, M, Kim, HJ et al. (2005). Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 106: 2530-2533. (Pubitemid 41510830)
58. Kiem, H P, Sellers, S, Thomasson, B, Morris, JC, Tisdale, JF, Horn, PA et al. (2004). Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. Mol Ther 9: 389-395. (Pubitemid 38404527)
59. Herndier, BG, Shiramizu, BT, Jewett, NE, Aldape, KD, Reyes, GR and McGrath, MS (1992). Acquired immunodefciency syndrome-associated T-cell lymphoma: evidence for human immunodefciency virus type 1-associated T-cell transformation. Blood 79: 1768-1774.
60. Brady, T, Agosto, LM, Malani, N, Berry, CC, O'Doherty, U and Bushman, F (2009). HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 23: 1461-1471.
61. Wang, GP, Levine, BL, Binder, GK, Berry, CC, Malani, N, McGarrity, G et al. (2009). Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modifed CD4+ T cells. Mol Ther 17: 844-850.
62. Beatty, J, Terry, A, MacDonald, J, Gault, E, Cevario, S, O'Brien, SJ et al. (2002). Feline immunodefciency virus integration in B-cell lymphoma identifes a candidate tumor suppressor gene on human chromosome 15q15. Cancer Res 62: 7175-7180. (Pubitemid 36025233)
63. Bell, P, Wang, L, Lebherz, C, Flieder, DB, Bove, MS, Wu, D et al. (2005). No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 12: 299-306. (Pubitemid 41025100)
64. Nakai, H, Montini, E, Fuess, S, Storm, TA, Grompe, M and Kay, MA (2003). AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34: 297-302. (Pubitemid 36792862)
65. Nakai, H, Wu, X, Fuess, S, Storm, TA, Munroe, D, Montini, E et al. (2005). Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 79: 3606-3614. (Pubitemid 40327949)
66. Donsante, A, Miller, DG, Li, Y, Vogler, C, Brunt, EM, Russell, DW et al. (2007). AAV vector integration sites in mouse hepatocellular carcinoma. Science 317: 477. (Pubitemid 47196106)
67. Themis, M, Waddington, SN, Schmidt, M, von Kalle, C, Wang, Y, Al-Allaf, F et al. (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 12: 763-771. (Pubitemid 41350158)
68. Bowers, WJ, Mastrangelo, MA, Howard, DF, Southerland, HA, Maguire-Zeiss, KA and Federoff, HJ (2006). Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector. Mol Ther 13: 580-588.
69. Gene Therapy Expert Group of the Committee for Proprietary Medical Products (CPMP); European Agency for the Evaluation of Medical Products (2004). Insertional mutagenesis and oncogenesis: update from non-clinical and clinical studies. Gene Therapy Expert Group of the Committee for Proprietary Medical Products (CPMP), European Agency for the Evaluation of Medical Products\June 2003 meeting. J Gene Med 6: 127-129.
70. Scobie, L, Hector, RD, Grant, L, Bell, M, Nielsen, AA, Meikle, S et al. (2009). A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Mol Ther 17: 1031-1038.
71. Bonini, C, Grez, M, Traversari, C, Ciceri, F, Marktel, S, Ferrari, G et al. (2003). Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9: 367-369. (Pubitemid 36460048)
72. Ciceri, F, Bonini, C, Stanghellini, MT, Bondanza, A, Traversari, C, Salomoni, M et al. (2009). Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 10: 489-500.
73. Deichmann, A, Hacein-Bey-Abina, S, Schmidt, M, Garrigue, A, Brugman, MH, Hu, J et al. (2007). Vector integration is nonrandom and clustered and infuences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117: 2225-2232. (Pubitemid 47219567)
74. Wang, GP, Garrigue, A, Ciuff, A, Ronen, K, Leipzig, J, Berry, C et al. (2008). DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res 36: e49. (Pubitemid 351737208)
75. Aiuti, A, Cassani, B, Andolf, G, Mirolo, M, Biasco, L, Recchia, A et al. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117: 2233-2240. (Pubitemid 47219568)
76. Uren, AG, Kool, J, Berns, A and van Lohuizen, M (2005). Retroviral insertional mutagenesis: past, present and future. Oncogene 24: 7656-7672. (Pubitemid 41670669)
77. Starr, TK and Largaespada, DA (2005). Cancer gene discovery using the Sleeping Beauty transposon. Cell Cycle 4: 1744-1748.
78. Cherry, SR, Biniszkiewicz, D, van Parijs, L, Baltimore, D and Jaenisch, R (2000). Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol Cell Biol 20: 7419-7426.
79. Hawley, RG, Lieu, FH, Fong, AZ and Hawley, TS (1994). Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1: 136-138. (Pubitemid 124000640)
80. Lu, M, Zhang, N, Maruyama, M, Hawley, RG and Ho, AD (1996). Retrovirus-mediated gene expression in hematopoietic cells correlates inversely with growth factor stimulation. Hum Gene Ther 7: 2263-2271. (Pubitemid 27021461)
81. Dupuy, AJ, Akagi, K, Largaespada, DA, Copeland, NG and Jenkins, NA (2005). Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436: 221-226. (Pubitemid 41021267)
82. Collier, LS, Carlson, CM, Ravimohan, S, Dupuy, AJ and Largaespada, DA (2005). Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436: 272-276. (Pubitemid 41021279)
83. Keng, VW, Villanueva, A, Chiang, DY, Dupuy, AJ, Ryan, BJ, Matise, I et al. (2009). A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 27: 264-274.
84. Starr, TK, Allaei, R, Silverstein, KA, Staggs, RA, Sarver, AL, Bergemann, TL et al. (2009). A transposon-based genetic screen in mice identifes genes altered in colorectal cancer. Science 323: 1747-1750.
85. Bell, JB, Aronovich, EA, Schreifels, JM, Clifford, AN, Hoekstra, ND, McIvor, RS et al. (2008). Expression of Sleeping Beauty transposase in mouse liver following hydrodynamic delivery. Mol Ther 16 (suppl. 1): S312.
86. Hackett, PB, Urness, M, Bell, JB, Olson, ER, Aronovich, EL, Cressman, E et al. (2008). Use of non-invasive balloon catheters placed under fuoroscopic guidance for delivery of the Sleeping Beauty transposon system under pressure to the liver of dogs. Mol Ther 16 (suppl. 1): S312.
87. Lander, ES, Linton, LM, Birren, B, Nusbaum, C, Zody, MC, Baldwin, J et al.; International Human Genome Sequencing Consortium (2001). Initial sequencing and analysis of the human genome. Nature 409: 860-921. (Pubitemid 32165345)
88. Waterston, RH, Lindblad-Toh, K, Birney, E, Rogers, J, Abril, JF, Agarwal, P et al.; Mouse Genome Sequencing Consortium (2002). Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520-562. (Pubitemid 35477048)
89. Charlesworth, B, Sniegowski, P and Stephan, W (1994). The evolutionary dynamics of repetitive DNA in eukaryotes. Nature 371: 215-220. (Pubitemid 24293018)
90. Lohe, AR, Moriyama, EN, Lidholm, DA and Hartl, DL (1995). Horizontal transmission, vertical inactivation, and stochastic loss of mariner-like transposable elements. Mol Biol Evol 12: 62-72.
91. Shapiro, JA and von Sternberg, R (2005). Why repetitive DNA is essential to genome function. Biol Rev Camb Philos Soc 80: 227-250. (Pubitemid 40712569)
92. Kazazian, HH Jr (2004). Mobile elements: drivers of genome evolution. Science 303: 1626-1632. (Pubitemid 38338313)
93. Kazazian, HH Jr and Goodier, JL (2002). LINE drive. retrotransposition and genome instability. Cell 110: 277-280.
94. Deininger, PL, Moran, JV, Batzer, MA and Kazazian, HH Jr (2003). Mobile elements and mammalian genome evolution. Curr Opin Genet Dev 13: 651-658.
95. Maksakova, IA, Romanish, MT, Gagnier, L, Dunn, CA, van de Lagemaat, LN and Mager, DL (2006). Retroviral elements and their hosts: insertional mutagenesis in the mouse germ line. PLoS Genet 2: e2.
96. Walisko, O, Schorn, A, Rolfs, F, Devaraj, A, Miskey, C, Izsvák, Z et al. (2008). Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. Mol Ther 16: 359-369. (Pubitemid 351168045)
97. Mouse Genome Sequencing Consortium, Waterston, RH, Lindblad-Toh, K, Birney, E, Rogers, J, Abril, J F, Agarwal, P et al. (2002). Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520-562. (Pubitemid 35477048)
98. Groth, AC, Olivares, EC, Thyagarajan, B and Calos, MP (2000). A phage integrase directs effcient site-specifc integration in human cells. Proc Natl Acad Sci USA 97: 5995-6000. (Pubitemid 30367512)
99. Thyagarajan, B, Olivares, EC, Hollis, RP, Ginsburg, DS and Calos, MP (2001). Site-specifc genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol 21: 3926-3934. (Pubitemid 32476454)
100. Olivares, EC, Hollis, RP, Chalberg, TW, Meuse, L, Kay, MA and Calos, MP (2002). Site-specifc genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol 20: 1124-1128. (Pubitemid 35285441)
101. Chalberg, TW, Portlock, JL, Olivares, EC, Thyagarajan, B, Kirby, PJ, Hillman, RT et al. (2006). Integration specifcity of phage phiC31 integrase in the human genome. J Mol Biol 357: 28-48. (Pubitemid 43339312)
102. Liu, J, Jeppesen, I, Nielsen, K and Jensen, TG (2006). Phi c31 integrase induces chromosomal aberrations in primary human fbroblasts. Gene Ther 13: 1188-1190. (Pubitemid 44084077)
103. Ehrhardt, A, Engler, JA, Xu, H, Cherry, AM and Kay, MA (2006). Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther 17: 1077-1094. (Pubitemid 44749710)
104. Yant, SR, Wu, X, Huang, Y, Garrison, B, Burgess, SM and Kay, MA (2005). High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 25: 2085-2094. (Pubitemid 40354609)
105. Xue, X, Huang, X, Nodland, SE, Mátés, L, Ma, L, Izsvák, Z et al. (2009). Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood 114: 1319-1330.
106. Singh, H, Manuri, PR, Olivares, S, Dara, N, Dawson, MJ, Huls, H et al. (2008). Redirecting specifcity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68: 2961-2971. (Pubitemid 351556297)
107. Huang, X, Wilber, AC, Bao, L, Tuong, D, Tolar, J, Orchard, PJ et al. (2006). Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood 107: 483-491. (Pubitemid 43076369)
108. Huang, X, Guo, H, Kang, J, Choi, S, Zhou, TC, Tammana, S et al. (2008). Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 16: 580-589. (Pubitemid 351314999)
109. Cornu, TI, Thibodeau-Beganny, S, Guhl, E, Alwin, S, Eichtinger, M, Joung, JK et al. (2008). DNA-binding specifcity is a major determinant of the activity and toxicity of zinc-fnger nucleases. Mol Ther 16: 352-358. (Pubitemid 351187464)
110. Coates, CJ, Kaminski, JM, Summers, JB, Segal, DJ, Miller, AD and Kolb, AF (2005). Site-directed genome modifcation: derivatives of DNA-modifying enzymes as targeting tools. Trends Biotechnol 23: 407-419.
111. Yant, SR, Huang, Y, Akache, B and Kay, MA (2007). Site-directed transposon integration in human cells. Nucleic Acids Res 35: e50. (Pubitemid 47073731)
112. Ivics, Z, Katzer, A, Stüwe, EE, Fiedler, D, Knespel, S and Izsvák, Z (2007). Targeted Sleeping Beauty transposition in human cells. Mol Ther 15: 1137-1144. (Pubitemid 46813616)
113. Voigt, K, Izsvák, Z and Ivics, Z (2008). Targeted gene insertion for molecular medicine. J Mol Med 86: 1205-1219.
114. Till, BG, Jensen, MC, Wang, J, Chen, EY, Wood, BL, Greisman, HA et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modifed autologous CD20-specifc T cells. Blood 112: 2261-2271.
115. Berger, C, Jensen, MC, Lansdorp, PM, Gough, M, Elliott, C and Riddell, SR (2008). Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118: 294-305.
116. Hinrichs, CS, Borman, ZA, Cassard, L, Gattinoni, L, Spolski, R, Yu, Z et al. (2009). Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 106: 17469-17474.
117. Shen, X, Zhou, J, Hathcock, KS, Robbins, P, Powell, DJ Jr, Rosenberg, SA et al. (2007). Persistence of tumor infltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 30: 123-129. (Pubitemid 46052211)
118. Sumiyoshi, T, Holt, NG, Hollis, RP, Ge, S, Cannon, PM, Crooks, GM et al. (2009). Stable transgene expression in primitive human CD34+ hematopoietic stem/ progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther 20: 1607-1626.
119. Izsvák, Z, Chuah, MK, Vandendriessche, T and Ivics, Z (2009). Effcient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods 49: 287-297.
120. Peng, PD, Cohen, CJ, Yang, S, Hsu, C, Jones, S, Zhao, Y et al. (2009). Effcient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specifc antitumor reactivity. Gene Ther 16: 1042-1049.
121. Hyland, KA, Olson, ER, Aronovich, EL, Hackett, PB, Blazar, BR, Tolar, JR et al. (2009). Analysis of Sleeping Beauty transposons for correction of Fanconi anemia in lymphoblastoid cell lines. Mol Ther 16 (suppl. 1): S119.
122. Kowolik, CM, Topp, MS, Gonzalez, S, Pfeiffer, T, Olivares, S, Gonzalez, N et al. (2006). CD28 costimulation provided through a CD19-specifc chimeric antigen receptor enhances in vivo persistence and antitumor effcacy of adoptively transferred T cells. Cancer Res 66: 10995-11004. (Pubitemid 44876999)
123. Editorial (2009). Gene therapy deserves a fresh chance. Nature 461: 1173.